WithdrawnPhase 2

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Stopped: Replaced it with another clinical trial

United States0Started 2019-10-31

Plain-language summary

The purpose of this study is to determine the effectiveness of relatlimab plus nivolumab, alone or in combination with various standard-of-care treatments in participants with gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma that has come back or spread to other places in the body after prior therapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Histologically or cytologically confirmed locally advanced or recurrent or metastatic GC or GEJ adenocarcinoma that is considered incurable by local therapies such as radiation or surgery * Evidence of progressive disease (PD) on at least one prior platinum- and fluoropyrimidine-containing chemotherapy regimen * Available tumor tissue for biomarker analysis Exclusion Criteria: * Must not have squamous cell or undifferentiated GC or GEJ * Untreated known central nervous system (CNS) metastases * Uncontrolled or significant cardiovascular disease Other protocol defined inclusion/exclusion criteria could apply

What they're measuring

Overall response rate (ORR)

Timeframe: Approximately 31 months

Trial details

NCT IDNCT03704077

SponsorBristol-Myers Squibb

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2022-02-27

View on ClinicalTrials.gov More Gastric Cancer trials